Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Parathyroid Hormone and Ischemic Cerebrovascular Event

Author(s): Hakan Altay*, Cihan Altın, Ali Coner, Haldun Muderrisoglu and Semih Giray

Volume 19, Issue 8, 2019

Page: [1134 - 1140] Pages: 7

DOI: 10.2174/1871530319666190215150410

Price: $65

Abstract

Background: Increased parathyroid hormone (PTH) level is associated with coronary artery disease, hypertension and left ventricular hypertrophy which are all predisposing factors for the ischemic cerebrovascular event (ICVE). Carotid intima-media thickness (CIMT) and aortic distensibility are the two early, subclinical predictors of atherosclerosis. The relation of PTH with CIMT and aortic distensibility in patients with ICVE has not been previously studied.

Objective: Our aim was to study the relationship of PTH levels with aortic distensibility and CIMT in patients with ICVE.

Methods: Sixty-four ICVE patients and 50 control group were enrolled in the study. PTH levels, aortic distensibility and CIMT were measured in all individuals.

Results: PTH levels were significantly higher in ICVE patients than in the controls (60.1±21.6 vs. 52.3±6.2 pg/ml) (p=0. 008). PTH levels were found to be inversely correlated with aortic distensibility (r= -0. 420, p=0.001) and positively correlated with CIMT (r:0, 285, p=0,002).

Conclusion: The present study shows that PTH levels are increased in patients with acute ischemic cerebrovascular event compared to the control group. It also demonstrates that PTH levels are inversely related to aortic distensibility of ascending aorta and positively associated with CIMT.

Keywords: Parathyroid hormone, atherosclerosis, cerebrovascular event, aortic distensibility, carotid intima-media thickness, atherosclerotic plaques.

« Previous Next »
Graphical Abstract

[1]
Altay, H.; Zorlu, A.; Binici, S.; Bilgi, M.; Yilmaz, M.B.; Çölkesen, Y.; Erol, T.; Muderrisoglu, H. Relation of serum parathyroid hormone level to severity of heart failure. Am. J. Cardiol., 2012, 109(2), 252-256.
[http://dx.doi.org/10.1016/j.amjcard.2011.08.039] [PMID: 21996143]
[2]
Grandi, N.C.; Breitling, L.P.; Hahmann, H.; Wüsten, B.; März, W.; Rothenbacher, D.; Brenner, H. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart, 2011, 97(15), 1215-1221.
[http://dx.doi.org/10.1136/hrt.2011.223529] [PMID: 21586795]
[3]
Kamycheva, E.; Sundsfjord, J.; Jorde, R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur. J. Cardiovasc. Prev. Rehabil., 2004, 11(1), 69-74.
[http://dx.doi.org/10.1097/01.hjr.0000114706.27531.01] [PMID: 15167209]
[4]
Vestergaard, P.; Mollerup, C.L.; Frøkjaer, V.G.; Christiansen, P.; Blichert-Toft, M.; Mosekilde, L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J. Surg., 2003, 27(2), 216-222.
[PMID: 12616440]
[5]
Piovesan, A.; Molineri, N.; Casasso, F.; Emmolo, I.; Ugliengo, G.; Cesario, F.; Borretta, G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin. Endocrinol. (Oxf.), 1999, 50(3), 321-328.
[http://dx.doi.org/10.1046/j.1365-2265.1999.00651.x] [PMID: 10435057]
[6]
Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; Lancellotti, P.; Muraru, D.; Picard, M.H.; Rietzschel, E.R.; Rudski, L.; Spencer, K.T.; Tsang, W.; Voigt, J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr., 2015, 28(1), 1-39.e14.
[http://dx.doi.org/10.1016/j.echo.2014.10.003] [PMID: 25559473]
[7]
Oztürk, D.; Ozcan Çelebi, O.; Ulusoy, F.V.; Aydoğdu, S. [The relationship between serum parathormone levels and the severity of coronary artery disease] Turk Kardiyol. Dern. Ars., 2012, 40(7), 589-594.
[http://dx.doi.org/10.5543/tkda.2012.49696] [PMID: 23363941]
[8]
Bro, S.; Olgaard, K. Effects of excess PTH on nonclassical target organs. Am. J. Kidney Dis., 1997, 30(5), 606-620.
[http://dx.doi.org/10.1016/S0272-6386(97)90484-4] [PMID: 9370175]
[9]
Ganesh, S.K.; Stack, A.G.; Levin, N.W.; Hulbert-Shearon, T.; Port, F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol., 2001, 12(10), 2131-2138.
[PMID: 11562412]
[10]
Hagström, E.; Hellman, P.; Larsson, T.E.; Ingelsson, E.; Berglund, L.; Sundström, J.; Melhus, H.; Held, C.; Lind, L.; Michaëlsson, K.; Arnlöv, J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation, 2009, 119(21), 2765-2771.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.808733] [PMID: 19451355]
[11]
Schierbeck, L.L.; Jensen, T.S.; Bang, U.; Jensen, G.; Køber, L.; Jensen, J.E. Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur. J. Heart Fail., 2011, 13(6), 626-632.
[http://dx.doi.org/10.1093/eurjhf/hfr016] [PMID: 21415099]
[12]
Altay, H.; Zorlu, A.; Bilgi, M.; Erol, T.; Yilmaz, M.B. Usefulness of parathyroid hormone as a predictor of heart failure with preserved ejection fraction. Biomarkers, 2012, 17(5), 447-454.
[http://dx.doi.org/10.3109/1354750X.2012.685182] [PMID: 22582762]
[13]
Nagashima, M.; Hashimoto, K.; Shinsato, T.; Ashida, K.; Kobayashi, M.; Yamashita, H.; Otsuka, M.; Naruko, T.; Itoh, A.; Haze, K. Marked improvement of left ventricular function after parathyroidectomy in a hemodialysis patient with secondary hyperparathyroidism and left ventricular dysfunction. Circ. J., 2003, 67(3), 269-272.
[http://dx.doi.org/10.1253/circj.67.269] [PMID: 12604880]
[14]
Stefenelli, T.; Mayr, H.; Bergler-Klein, J.; Globits, S.; Woloszczuk, W.; Niederle, B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am. J. Med., 1993, 95(2), 197-202.
[http://dx.doi.org/10.1016/0002-9343(93)90260-V] [PMID: 8356983]
[15]
Jia, C.F.; Wang, Z.Q.; Sun, X.X.; Yang, Z.Q.; Zou, Y.J.; Jiang, Y.N. Ascending aortic distensibility and target organ damage in primary hypertension without diabetes. Int. J. Cardiovasc. Imaging, 2017, 33(8), 1245-1251.
[http://dx.doi.org/10.1007/s10554-017-1099-x] [PMID: 28299609]
[16]
Yuksel Kalkan, G.; Gur, M.; Eksi Haydardedeoğlu, F.; Kırım, S.; Baykan, A.O.; Kuloğlu, O.; Ucar, H.; Sahin, D.Y.; Elbasan, Z. seker T, Turkoglu C, Yıldırım A, Caylı M. The association between aortic distensibility and coronary flow reserve in newly diag-nosed diabetic patients. Echocardiography, 2015, 32, 205-212.
[http://dx.doi.org/10.1111/echo.12631] [PMID: 24815036]
[17]
Özdemir, B.; Emül, A.; Özdemir, L.; Sağ, S.; Biçer, M.; Aydınlar, A. Association of aortic diameters with coronary artery disease severity and albümin excretion. BioMed Res. Int., 2015.2015857628
[http://dx.doi.org/10.1155/2015/857628] [PMID: 26413550]
[18]
Cohoon, K.P.; Criqui, M.H.; Budoff, M.J.; Lima, J.A.; Blaha, M.J.; Decker, P.A.; Durazo, R.; Liu, K.; Kramer, H. Relationship of aor-tic Wall distensibility to mitral and aortic valve calcification: the multi-ethnic study of atherosclerosis. Angiology, 2018, 69(5), 443-448.
[http://dx.doi.org/10.1177/0003319717730636] [PMID: 29025284]
[19]
Adenwalla, S.F.; Graham-Brown, M.P.M.; Leone, F.M.T.; Burton, J.O.; McCann, G.P. The importance of accurate measurement of aortic stiffness in patients with chronic kidney disease and end-stage renal disease. Clin. Kidney J., 2017, 10(4), 503-515.
[http://dx.doi.org/10.1093/ckj/sfx028] [PMID: 28852490]

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy